Industry News

Join WhatsApp Channel 

Regulatory Affairs Courses
  • New Hope for COPD Patients as AstraZeneca Drug Shows Strong Results in Major Trial
    20 April 2026

    New Hope for COPD Patients as AstraZeneca Drug Shows Strong Results in Major Trial

    A new experimental drug from AstraZeneca is giving fresh hope to millions of people living with Chronic Obstructive Pulmonary Disease after showing positive results in a large late-stage study.

    The drug, Tozorakimab, met its main goal in the Phase III MIRANDA trial. It helped reduce the number of serious flare-ups, also called exacerbations, in patients who were already taking standard inhaled treatments but still had symptoms.

  • Piramal Critical Care has successfully closed the acquisition of Kenalog
    17 April 2026
    Piramal Critical Care has successfully closed the acquisition of Kenalog
    Kenalog® is a well-established injectable therapy with a long-standing legacy in the treatment of inflammatory conditions, marketed across 15 countries under trusted brands including Kenalog®, Kenacort®, Trigon®, and Adcortyl®.
  • Eli Lilly announced results of Jaypirca (pirtobrutinib)
    15 April 2026
    Eli Lilly announced results of Jaypirca (pirtobrutinib)

    Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Treatment in both study arms was administered for up to two years, after which patients do not take any CLL therapy until their disease progresses. 

  • Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026
    15 April 2026
    Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026

    Johnson & Johnson today announced favorable 12-month interim effectiveness and safety results from VARIPURE, the largest prospective post-market follow-up study evaluating first-time pulsed field ablation (PFA) using the VARIPULSE Platform. The data were presented at the PFA Summit during the 2026 European Heart Rhythm Association (EHRA) Annual Meeting in Paris and simultaneously published in Europace.

  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the USA
    10 April 2026
    Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the USA
    Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg.
  • Amgen announced results from a Phase 3 trial of TEPEZZA
    10 April 2026
    Amgen announced results from a Phase 3 trial of TEPEZZA
    Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease
  • Novo Nordisk : Awiqli® approved in the USA
    27 March 2026
    Novo Nordisk : Awiqli® approved in the USA
    Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes.
  • Zydus Lifesciences & Torrent Pharmaceuticals Partner to Co-Market Semaglutide in India
    18 March 2026
    Zydus Lifesciences & Torrent Pharmaceuticals Partner to Co-Market Semaglutide in India
    Zydus Lifesciences Limited an innovation-led global life-sciences company and Torrent Pharmaceuticals Limited a specialty-focused global pharmaceutical company, have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market.
  • Moderna Settles Vaccine Patent Dispute with 950 Million USD Deal
    5 March 2026
    Moderna Settles Vaccine Patent Dispute with 950 Million USD Deal
    Biotechnology company Moderna has announced a major settlement to resolve global patent litigation with Arbutus Biopharma Corporation and Genevant Sciences GmbH over technology used in its mRNA vaccines. The agreement settles all ongoing lawsuits worldwide related to the companies’ disputes.
  • Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
    5 March 2026
    Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
    The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD).
Subscribe to Industry News